Covidien introduces permacol(TM) biologic implant





Covidien, a leading global provider of healthcare products, announced the launch of Permacol(TM) Biologic Implant, a biologic mesh for hernia repair. Permacol(TM), which joins the Company's line of products following the acquisition of Tissue Science Laboratories, is available in the United States, Europe, Canada and Korea and will be registered in other markets starting in 2009.

Covidien, a leading global provider of healthcare products, announced the launch of Permacol(TM) Biologic Implant, a biologic mesh for hernia repair. Permacol(TM), which joins the Company's line of products following the acquisition of Tissue Science Laboratories, is available in the United States, Europe, Canada and Korea and will be registered in other markets starting in 2009.

Scott Flora, President, Surgical Devices, Covidien said, As a leader in soft tissue repair, Covidien now offers the optimal hernia repair product for individual patient needs, including biologic implants, synthetic mesh, fixation and dissection devices.

Permacol(TM) Biologic Implant contains enhanced porcine collagen for complex hernias and abdominal wall repairs. The product combines the clinical advantages of a biologic with the strength, size, and intraoperative efficiency of a synthetic in an accellular porcine dermal implant. Permacol(TM) Biologic Implant, which is hydrated and ready-to-use, can be cut or shaped to size as needed and provides a stable, durable soft tissue repair.